239 related articles for article (PubMed ID: 31206526)
21. A novel harmine derivative, N-(4-(hydroxycarbamoyl)benzyl)-1-(4- methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxamide (HBC), as histone deacetylase inhibitor: in vitro antiproliferation, apoptosis induction, cell cycle arrest, and antimetastatic effects.
Miao JF; Peng YF; Chen S; Gao WJ; Yang QX; Zhu P; Guo J; Tao J; Luo L; Zhang Y; Ling Y
Eur J Pharmacol; 2018 Apr; 824():78-88. PubMed ID: 29428472
[TBL] [Abstract][Full Text] [Related]
22. Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK Pathway.
Hsu FS; Wu JT; Lin JY; Yang SP; Kuo KL; Lin WC; Shi CS; Chow PM; Liao SM; Pan CI; Hong JY; Chang HC; Huang KH
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866433
[TBL] [Abstract][Full Text] [Related]
23. Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach.
Li QQ; Hao JJ; Zhang Z; Hsu I; Liu Y; Tao Z; Lewi K; Metwalli AR; Agarwal PK
Int J Oncol; 2016 Jun; 48(6):2591-607. PubMed ID: 27082124
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.
Li LH; Zhang PR; Cai PY; Li ZC
Biomed Pharmacother; 2016 Aug; 82():161-6. PubMed ID: 27470351
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation-mediated p21
Tseng TH; Chien MH; Lin WL; Wen YC; Chow JM; Chen CK; Kuo TC; Lee WJ
Environ Toxicol; 2017 Feb; 32(2):434-444. PubMed ID: 26872304
[TBL] [Abstract][Full Text] [Related]
26. The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway.
Sarfstein R; Bruchim I; Fishman A; Werner H
PLoS One; 2011; 6(9):e24468. PubMed ID: 21931726
[TBL] [Abstract][Full Text] [Related]
27. Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells.
Okubo K; Isono M; Miyai K; Asano T; Sato A
Cancer Sci; 2020 Jan; 111(1):112-126. PubMed ID: 31675763
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.
Richon VM; Sandhoff TW; Rifkind RA; Marks PA
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10014-9. PubMed ID: 10954755
[TBL] [Abstract][Full Text] [Related]
29. A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes.
Liu Z; Ding K; Li L; Liu H; Wang Y; Liu C; Fu R
Biomed Pharmacother; 2016 Oct; 83():1032-1037. PubMed ID: 27541047
[TBL] [Abstract][Full Text] [Related]
30. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
You BR; Han BR; Park WH
Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
[TBL] [Abstract][Full Text] [Related]
31. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.
Park SE; Kim HG; Kim DE; Jung YJ; Kim Y; Jeong SY; Choi EK; Hwang JJ; Kim CS
Invest New Drugs; 2018 Apr; 36(2):195-205. PubMed ID: 29110173
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase inhibitors suppress the growth of human osteosarcomas in vitro and in vivo.
Wu Z; Ma C; Shan Z; Ju Y; Li S; Zhao Q
J BUON; 2013; 18(4):1032-7. PubMed ID: 24344034
[TBL] [Abstract][Full Text] [Related]
33. p21 and p53 Immunostaining and survival following systemic chemotherapy for urothelial cancer.
Jankevicius F; Goebell P; Kushima M; Schulz WA; Ackermann R; Schmitz-Dräger BJ
Urol Int; 2002; 69(3):174-80. PubMed ID: 12372883
[TBL] [Abstract][Full Text] [Related]
34. Chemosensitivity enhancement toward arsenic trioxide by inhibition of histone deacetylase in NB4 cell line.
Li X; Guan X; Li F; Chen Y; Li N
J Int Med Res; 2016 Aug; 44(4):882-92. PubMed ID: 27189198
[TBL] [Abstract][Full Text] [Related]
35. Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo.
Tzao C; Jin JS; Chen BH; Chung HY; Chang CC; Hsu TY; Sun GH
Dis Esophagus; 2014; 27(7):693-702. PubMed ID: 24033428
[TBL] [Abstract][Full Text] [Related]
36. Suberoylanilide Hydroxamic Acid Can Re-sensitize a Cisplatin-Resistant Human Bladder Cancer.
Ryu H; Jin H; Ho JN; Bae J; Lee E; Lee SE; Lee S
Biol Pharm Bull; 2019; 42(1):66-72. PubMed ID: 30606990
[TBL] [Abstract][Full Text] [Related]
37. Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody.
Booth L; Roberts JL; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(1):109-121. PubMed ID: 30142009
[TBL] [Abstract][Full Text] [Related]
38. HDAC inhibition in glioblastoma monitored by hyperpolarized
Radoul M; Najac C; Viswanath P; Mukherjee J; Kelly M; Gillespie AM; Chaumeil MM; Eriksson P; Delos Santos R; Pieper RO; Ronen SM
NMR Biomed; 2019 Feb; 32(2):e4044. PubMed ID: 30561869
[TBL] [Abstract][Full Text] [Related]
39. Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells.
Liu ZH; Li J; Xia J; Jiang R; Zuo GW; Li XP; Chen Y; Xiong W; Chen DL
Chem Biol Interact; 2015 Dec; 242():227-34. PubMed ID: 26482938
[TBL] [Abstract][Full Text] [Related]
40. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
